Free tool
FAERS Monitor: Hetlioz
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205677 or its brand name (Hetlioz, Tasimelteon). Reports on generic versions are filed under their own applications.
Reports
5,773
Serious
600
10% of reports
Hospitalization
287
Death reported
166
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,636
- insomnia730
- product dose omission issue475
- middle insomnia412
- somnolence409
- headache386
- nightmare268
- abnormal dreams224
- fatigue224
- therapeutic product effect decreased193
- sleep disorder189
- inappropriate schedule of product administration185
- incorrect product administration duration165
- poor quality sleep155
- initial insomnia152
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 9 |
| 2015 | 577 |
| 2016 | 408 |
| 2017 | 308 |
| 2018 | 540 |
| 2019 | 776 |
| 2020 | 741 |
| 2021 | 730 |
| 2022 | 550 |
| 2023 | 559 |
| 2024 | 331 |
| 2025 | 150 |
| 2026 | 94 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,386 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| middle insomniaSignal | 412 | 82.2 | 74.8 | 32,262 |
| initial insomniaSignal | 152 | 54.8 | 46.8 | 7,856 |
| abnormal dreamsSignal | 224 | 29.8 | 26.2 | 6,161 |
| nightmareSignal | 268 | 28.4 | 25.3 | 7,023 |
| incorrect product administration durationSignal | 165 | 28.0 | 24.0 | 4,233 |
| poor quality sleepSignal | 155 | 26.4 | 22.6 | 3,741 |
| therapeutic product effect decreasedSignal | 193 | 15.8 | 13.7 | 2,648 |
| insomniaSignal | 730 | 10.0 | 9.4 | 5,971 |
| sleep disorderSignal | 189 | 9.8 | 8.5 | 1,482 |
| somnolenceSignal | 409 | 7.4 | 6.8 | 2,280 |
| product dose omission issueSignal | 475 | 5.9 | 5.4 | 1,949 |
| drug ineffectiveSignal | 1,636 | 4.5 | 4.3 | 4,786 |
| inappropriate schedule of product administrationSignal | 185 | 3.7 | 3.2 | 372 |
| headacheSignal | 386 | 2.2 | 2.0 | 273 |
| fatigue | 224 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.